No Data
No Data
BofA Securities Downgrades Lyell Immunopharma(LYEL.US) to Sell Rating, Cuts Target Price to $0.6
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Rhythm Pharmaceuticals (RYTM) and Lyell Immunopharma (LYEL)
Lyell to Highlight Vision for Its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
Bank of America Securities Sticks to Its Sell Rating for Lyell Immunopharma (LYEL)
Morgan Stanley Maintains Lyell Immunopharma(LYEL.US) With Hold Rating, Maintains Target Price $4
Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround